POM-V Prescription Required

Toxovax Concentrate and Solvent for Suspension for Injection for Sheep

Active ingredient: Toxoplasma gondii

Form

Injection

Species

Sheep

Manufacturer

Intervet International B.V.

VMD MA No.

06376/4102

What it's used for

Duration of immunity: Vaccination with the veterinary medicinal product is known to protect for at least two lambing seasons.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Toxoplasma gondii

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Toxovax Concentrate and Solvent for Suspension for Injection for Sheep — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Duration of immunity: Vaccination with the veterinary medicinal product is known to
protect for at least two lambing seasons.

Immediately before use this is added to the 40 or 100 ml (respectively) solvent
(Unisolve), giving a dose volume of 2 ml.
Injection equipment
To minimise the risk of self-injection the vaccine should be administered using
disposable automatic syringes fitted with a guarded needle system according to the
manufacturer's instructions.
An administration kit including a vented transfer device for vaccine reconstitution and
disposable automatic syringe with a guarded needle system is available from the
company.
It is vital that a vented draw off tube is used with this equipment. Regular checks
should be made to ensure the syringes are properly calibrated.
Carefully attach the vial of reconstituted vaccine to the injection equipment and avoid
creating aerosols during the priming process. It may be advisable to wear a visor
while carrying out this operation.
Reconstitution:
Protective gloves (impervious rubber or plastic such as disposable medical gloves or
surgical gloves (EU standards)) and goggles or a face visor should be worn when
reconstituting the vaccine.
If using the vented transfer device push one end of the device through the centre of
the solvent vial using a firm, twisting action. Similarly, push the vaccine vial onto the
opposite end of the device taking care to ensure the spike penetrates the centre of
the vial bung. The vaccine concentrate will drain into the solvent vial. Remove the
empty vaccine vial and transfer spike from the solvent vial and place into an
appropriate disinfectant solution.
Alternatively, withdraw the entire contents of the vaccine concentrate vial using a
sterile disposable 10 ml syringe and either a 16 G or 18 G sterile needle. Carefully
expel any air from the syringe and inject the contents into the solvent vial.
With the solvent vial upright withdraw 5-10 ml of air prior to removing the needle. This
maintains the vial under negative pressure and avoids spillage when the needle is
removed.
After reconstitution the vaccine should be kept cool and away from light and used as
soon as possible (within 2 hours).
Ideally only reconstitute one vaccine vial at a time.
Administration
Intramuscular use.
Dose: 2 ml.
Basic vaccination:
Animals should be given a single dose at least 3 weeks prior to mating. Ewe lambs,
where it is intended to breed from them, may be vaccinated from 5 months of age.
Shearlings and older ewes should be vaccinated during the 4 month period prior to
mating.
Revaccination:
After 2 years, a single dose at least 3 weeks prior to mating.
Visual appearance after reconstitution: Cloudy suspension.

Do not vaccinate animals less than 3 weeks before mating.
Do not use during pregnancy.

Sheep (ewes):
Very common
(>1 animal / 10 animals
treated):
Hyperthermia
.
Transient, up to 41°C is normally observed. The temperature returns to normal
within 7-8 days after vaccination.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

Toxoplasma is only one of the causes of abortion in sheep.
Where abortion occurs in sheep which have been vaccinated with the veterinary
medicinal product then it is recommended that veterinary advice is sought
immediately to clarify the likely cause.
Care should be taken when handling such abortions as susceptible humans may be
at risk of infection.
A good immune response is reliant on the reaction of an immunogenic agent and a
fully competent immune system.
Immunogenicity of the vaccine antigen will be reduced by poor storage or
inappropriate administration.
Immunocompetence of the animal may be compromised by a variety of factors
including poor health, nutritional status, genetic factors, concurrent drug therapy and
stress.
Vaccinate healthy animals only.

Special precautions for safe use in the target species:
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Care should be taken to avoid accidental self-injection and to avoid vaccine getting
into the mouth or the eyes.
In case of accidental self-injection, ingestion or spillage onto skin, seek medical
advice immediately and show the package leaflet or the label to the physician. The
physician should be informed that self-injection with a living tachyzoite toxoplasma
vaccine has occurred.
Pyrimethamine therapy is the current recognised treatment for toxoplasmosis in
humans.
Personal protective equipment consisting of gloves should be worn when handling
the veterinary medicinal product.
The veterinary medicinal product should not be handled by pregnant women, or
women of childbearing age as the vaccine may interfere with normal foetal
development.
Living tachyzoites can be pathogenic for humans. Since this vaccine has been
prepared with live, attenuated microorganisms, appropriate measures should be
taken to prevent contamination of the handler and other people that collaborate in the
process.
Immunocompromised persons are advised to avoid contact with the vaccine (e.g.,
AIDS sufferers; persons undergoing chemotherapy or taking immunosuppressive
drugs).
Special precautions for the protection of the environment:
Not applicable.

Safety and efficacy data are available which demonstrate that this vaccine can be
administered on the same day but not mixed with Enzovax. The vaccines should be
given at different sites.
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product except the product mentioned above.
A decision to use this vaccine before or after any other veterinary medicinal product
therefore needs to be made on a case-by-case basis.

Concentrate:
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.
Solvent (Unisolve):
Store below 25 °C (if stored separately).
Do not freeze.

Meat and offal: 42 days.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.